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We report a 57-year old man with polycythemia vera, who had a remarkable hematological and mole-
cular response during treatment with simvastatin and alendronate. The patient was treated with this
combination for 56 months, and during this period the patient has been in complete hematological
remission. The JAK2-V617F allele burden has dropped from 64% to sustained values below 20%, and
follow-up bone marrow biopsies have revealed no change in PV features, without any regular cytor-
eductive treatment.
& 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Case report
In 2008 a 57-year old man was referred for treatment of
polycythemia vera (PV). One year earlier he had been admitted
with symptoms resembling an episode of transitory cerebral
ischemia (TCI). The patient also had a history of multiple sclerosis
(MS), vitamin B12 deﬁciency and tobacco smoking. The MS was
not being treated at this point and the B12 deﬁciency was treated
with cyanocobalamin 1 mg/day. At that time the hemoglobin
concentration (Hgb) was elevated at 18.5 g/dL, the hematocrit
(HCT) was 54%, and the white blood cell count (WBC) was
11.0109/L. The platelet count was 502109/L. Mean corpuscular
volume (MCV) was normal 97 fL. A cerebral CT-scan showed a
hypodense area compatible with an infarction of indeterminable
age. The patient was treated with acetylsalicylic acid 75 mg/day,
dipyridamole 200 mg 2 times/day along with simvastatin 40 mg/
day. The patient was phlebotomized once before discharge. Un-
fortunately, although the elevated blood cells should have raised
the suspicion of PV, the patient was not referred to a department
of hematology, and no JAK2-V617F mutation analysis was done at
this time.
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Hgb-concentrations and platelet counts along with fatigue. At the
time of the PV diagnosis the Hgb concentration was 19.2 g/dL and
the HCT 0.60. The WBC was 12.0109/L, and the platelet count
485109/L, the MCV 91 fL and B12 vitamin was elevated at
882 pmol/l. MCV remained normal and B12 normal or elevated.
The red cell mass and plasma volume were both expanded, and
serum-EPO was lowered at 1 IU/L. The JAK2-V617F mutation was
positive with an allele burden of 64%. A bone marrow biopsy was
compatible with PV with a slightly hypercellular bone marrow
with panmyelosis and depleted iron stores, displaying no reticulin
ﬁbrosis and a peripheral blood-smear was without leucoerythro-
blastosis. Immunohistochemical staining with CD34 showed di-
lated vessels, but no increase in vascular density. An abdominal
ultrasound showed normal spleen size. Based on the above ﬁnd-
ings the diagnosis PV was made.
During the following year 11 phlebotomies were performed
and no cytoreductive treatment was administered. Fig. 1 illustrates
the treatment and responses in hematological parameters along
with the JAK2-V617F allele burden. Approximately 13 months after
the PV-diagnosis, treatment with hydroxyurea (HU) 500 mg/day
was initiated in order to reduce the need of phlebotomies and to
normalize elevated leukocyte and platelet counts. Eighteen days
later the patient was admitted to a department of neurology with
convulsions and fever, being suspected of an attack of MS. Clini-
cally a pneumonia was suspected, and a chest x-ray revealednder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. The development of hematological parameters and the JAK2-V617F allele burden and an overview of the treatment.
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biotics was initiated. No bacterial growth from blood, urine or
sputum was recorded. After 3 days of admission HU was dis-
continued. Later, the patient developed shock and was transferred
to the intensive care unit. A CT-scan of the chest and abdomen
revealed signs of pulmonary alveolitis. A bronchoscopy was nor-
mal. No biopsy was performed. It was concluded that the alveolitis
likely was induced by HU, since the patient steadily improved after
HU was discontinued.
At follow-up in the hematological out-patient clinic the patient
had a normal HCT and the platelet count was slightly elevated at
515109/L. However, no further cytoreductive treatment wasFig. 2. Bone marrow biopsies finitiated. At the beginning of 2011 (31 months after the PV-diag-
nosis) osteoporosis was diagnosed. Consequently, treatment with
alendronate 70 mg/week was initiated and continued for 18
months, until the patient changed treatment to Teriparatide – a
PTH analog – for two years. Afterwards alendronate was re-
introduced. During these 56 months, after initiation of alen-
dronate, the patient was largely in complete hematological re-
mission (the platelet count was temporarily above 400109/L on
some occasions) without need for further phlebotomies, and the
JAK2-V617F mutation status 44 months after PV-diagnosis re-
vealed a marked decrease in the allele burden from 64.0% to 21.4%
(Fig. 1). The patient had no need of phlebotomies or cytoreductiverom 2008, 2013 and 2015.
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rhagic events occurred. Subsequent serial measurements of the
JAK2-V617F allele burden have shown sustained values below 20%
and even below 10% on some occasions. Two follow-up bone
marrow biopsies at 33 and 53 months after institution of statin
and bisphosphonate combination therapy (64 and 84 months after
PV-diagnosis) displayed stable disease with remaining features of
PV. Despite this, the vascular dilatation found in the initial bone
marrow biopsy had disappeared in the two following biopsies
(Fig. 2).2. Discussion
This case report demonstrates for the ﬁrst time a remarkable
hematological and molecular response with a marked sustained
decrease in the JAK2-V617F allele burden during statin and bi-
sphosphonate combination therapy of a patient with PV. Both
agents potently inhibit the mevalonate pathway, which has been
suggested as a therapeutic target in multiple cancer types [1] and
also in the treatment of MPNs [2]. An association between chronic
inﬂammation and the development and progression of MPNs has
been proposed [3], and both statins and bisphosphonates possess
potent anti-inﬂammatory, anti-neoplastic, anti-thrombotic and
anti-angiogenic properties unrelated to the cholesterol lowering
effects of statins [1,2,4]. These effects are probably mediated by
inhibiting the synthesis of the important isoprenoid intermediates
such as farnesylpyrophosphate (FPP) and geranylgeranylpyropho-
sphate (GGP). These intermediates are important in the post-
translational modiﬁcation of a variety of proteins. When activated
these pathways induce increased cellular growth, proliferation,
migration and oxidative stress. Accordingly, their inhibition might
theoretically dampen inﬂammation and ultimately tumor devel-
opment [1,4]. Importantly, simvastatin (and other statins) induce
apoptosis and inhibit JAK2-V617F-dependent cell growth in MPN
cell lines. Furthermore, the MPN-associated JAK2-V617F kinase
localization to lipid rafts and its signaling is inhibited by statins
[5]. Also, the pro-inﬂammatory cytokines TNF-alpha and IL-6 are
decreased during statin treatment in a wide variety of in-
ﬂammatory conditions [6], TNF-alpha being able to facilitate clonal
expansion of JAK2-V617F-positive cells in MPNs [7]. Both statins
and bisphosphonates inhibit the release of VEGF. VEGF mediated
neo-angiogenesis may in part be responsible for the bone marrow
ﬁbrosis observed in myeloﬁbrosis [1,2]. This effect may be ob-
served in the bone marrow of this patient, where the CD34
staining revealed vascular dilatation in 2008 but not in the fol-
lowing two biopsies. Release of VEGF from the tumor cells may be
responsible for the vascular dilatation observed [8].
Regarding the reduction in JAK2-V617F allele burden, the pa-
tient only received treatment with HU for 18 days during the in-
itial disease course. Thus, it is reasonable to conclude, that the
ensuing marked decrease in the JAK2-V617F allele burden over the
ﬁrst 44 months after the PV diagnosis was not related to HU-
treatment. Although HU has been shown to reduce the JAK2-V617F
allele burden in some studies, other studies have failed to re-
produce this effect [9]. Importantly, the effect of HU on peripheral
blood cell counts and the JAK2-V617F allele burden is but tem-
porary with rising cell counts within a few days after HU being
discontinued. We believe that the response is a result of the
treatment with simvastatin and from month 31 the addition of
alendronate. However, since 44 months elapsed between the ﬁrst
two JAK2-V617F analyses, we are unable to relate the decrease in
the JAK2-V617F allele burden directly to the initiation of alen-
dronate treatment. Interestingly, during the two years of ter-
iparatide treatment, when alendronate was paused, the JAK2-
V617F allele burden was relatively stable. The followingstabilization of the disease parameters might suggest that a long-
term bisphosphonate treatment is redundant, and instead a short-
term treatment plan with bisphosphonate followed by continuous
statin treatment might be a better strategy. During this period the
patient was treated with the platelet inhibitors ASA and dipyr-
amidole. Dipyramidole is a phosphodiesterase inhibitor similar to
anagrelide which is used in the treatment of essential thrombo-
cytosis to reduce platelet count, but not in the standard treatment
of PV [10]. Dipyramidole has been shown to inhibit the prolifera-
tion of peripheral blood mononuclear cells from patients with CML
and AML in-vitro [11], and could have inﬂuenced the hematolo-
gical response in this patient. On the other hand dipyramidole can
also stimulate hematopoietic reconstitution in irradiated mice
[12]. No studies have shown an effect on human blood cell counts
in-vivo. Thus, we do not believe that dipyramidole is responsible
for the remarkable response. Likewise, there is no evidence to
suggest that ASA could have caused the response.
Prior case reports have described hematological remission in
patients with myeloﬁbrosis during treatment with bispho-
sphonates, but a phase II study investigating the effects of zole-
dronic acid on patients with myeloﬁbrosis showed responses in
only 1 of 16 patients[13].
In conclusion, we report complete hematological response in
concert with a partial molecular response in a patient with PV
treated with alendronate and simvastatin. Although bispho-
sphonate monotherapy – as illustrated by Delforge et al. [13] – may
rarely be beneﬁcial in the late myeloﬁbrosis stage, the highly re-
markable response in our patient on combination therapy with
statin and bisphosphonate, possibly exhibiting different but sy-
nergistic blocking effects in the mevalonate pathway, is certainly
an encouraging stimulus for further experimental and clinical re-
search on the potential role of these “old drugs” in the treatment of
MPNs alone or adjuvant to HU, interferon-2a or JAK1/2 inhibitors
[3]. Furthermore, a greater response may be expected in the earlier
stages of the MPN disease (ET or PV), before the bone marrow
becomes ﬁbrotic. Besides, a relatively small number of responders
may still be beneﬁcial, when taking into account the relatively low
toxicity of these treatments.Conﬂict of interests
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